This allows Metabolon to work with academic and industrial scientists within China or other Asian countries to perform biochemical profiling experiments with Metabolon’s technology.
“The successful launch of the joint lab is a vital step in bringing the science of metabolomics to a significant, untapped market,” states Metabolon CEO John Ryals. “Our partnership with Shanghai Jiao Tong University is a further proof of Metabolon’s efforts to bring personalized medicine and metabolic biomarker research to all parts of the world. We were able to completely replicate our complex mass spectrometry based methods in a remote location due to our highly engineered and quality controlled process. This will open up expansion possibilities for Metabolon to service previously difficult to access markets across the globe.”